PerpEquities

Kodiak Sciences Inc. (KOD) cash flow statement

NASDAQ · Healthcare · Biotechnology · 141 employees · CEO Victor Perlroth

Price
$99.18 -1.22%
Market cap
$6.23B
Enterprise value
$6.2B
Last report
Q2 '26 filed 2026-08-13
Next report
2026-11-12 EPS est. -$1.06

In Q2 '26 Kodiak Sciences Inc. (KOD) generated -$46.2M of operating cash flow, invested $352K in capital expenditure and kept -$46.6M of free cash flow. Over the last four quarters free cash flow was -$160M.

Cash flow

Cash flowTrendQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Operating
Net income-$50M-$59.5M-$43M-$45.1M-$43.9M-$44.1M-$57.5M-$54.3M-$61.5M-$56.7M-$58.2M-$65.6M
Depreciation & amortization$6.97M$6.66M$6.65M$6.68M$6.7M$6.68M$6.73M$6.54M$6.54M$6.52M$6.34M$6.19M
Stock-based compensation$13.9M$22.8M$18.4M$18.4M$14.8M$8.62M$15.9M$15.6M$14M$27.3M$12.2M$11.6M
Deferred income tax-$314K-$33.7M$0$0$0$0$0$0$0$0$0$0
Change in working capital-$3.67M-$2.53M-$21.8M-$6.64M$1.28M-$1.27M$3.85M-$2.54M$7.99M-$2.45M-$346K$627K
Other non-cash items$314K$34M$144K$211K$0$0$1.92M$0$0-$14M$0$982K
Operating cash flow-$32.8M-$32.2M-$39.6M-$26.5M-$21.2M-$30.1M-$29.1M-$34.7M-$32.9M-$39.4M-$40M-$46.2M
Investing
Capital expenditure-$226K-$27.5M-$22K-$49K-$205K-$124K-$270K-$133K-$60K-$43K-$942K-$352K
Purchases of investments$0$0$0$0-$355K$0$0$0$0$0$0$0
Sales / maturities of investments$0-$314K$0$0$0$0$0$0$0$0$0$0
Other investing$0$0-$144K-$211K$355K$0$0$0$0$0$0$0
Investing cash flow-$226K-$27.8M-$166K-$260K-$205K-$124K-$270K-$133K-$60K-$43K-$942K-$352K
Financing
Other financing (incl. tax on vested shares)-$12K-$175K$0$0-$59K$0$0$0$0$0$0$0
Financing cash flow-$12K-$124K$38K$59K$0$404K$124K$120K$813K$177M$619K$2.96M
Summary
FX effect on cash$0$0$140K$0$0$0$0$0$0$0$0$0
Net change in cash-$33M-$60.2M-$39.6M-$26.7M-$21.4M-$29.8M-$29.2M-$34.7M-$32.1M$138M-$40.3M-$43.6M
Free cash flow (OCF - capex)-$33M-$59.7M-$39.6M-$26.5M-$21.4M-$30.2M-$29.3M-$34.8M-$32.9M-$39.4M-$41M-$46.6M

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data as of 2026-11-02